- Kezar Life Sciences Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Kezar Life Sciences Inc at Wells Fargo Healthcare Conference TranscriptSep 07, 2023
- Kezar Life Sciences Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Kezar Life Sciences Inc R&D Day TranscriptMar 15, 2023
- Alpine Immune Sciences Inc and Kezar Life Sciences Inc at Cowen Health Care Conference- Panel TranscriptMar 07, 2023
- Kezar Life Sciences Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Kezar Life Sciences Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 30, 2022
- Kezar Life Sciences Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Kezar Life Sciences Inc Topline Results from the MISSION Phase 2 Clinical Trial Evaluating Zetomipzomib - Corporate Call TranscriptJun 27, 2022
- Kezar Life Sciences Inc Annual Shareholders Meeting TranscriptJun 25, 2021
- Kezar Life Sciences Inc At TMA's International Annual Patient Conference TranscriptSep 22, 2020
- Q2 2020 Kezar Life Sciences Inc Earnings Call TranscriptAug 05, 2020$4.72 (+1.83%)Earnings
- Kezar Life Sciences Inc At MSU: Rare Disease Day Presentation TranscriptApr 15, 2020
- Kezar Life Sciences Inc At PRESIDIO Clinical Trial of KZR-616 TranscriptMar 05, 2020
Kezar Life Sciences Inc Topline Results from the MISSION Phase 2 Clinical Trial Evaluating Zetomipzomib - Corporate Call Transcript
Welcome to Kezar Life Sciences 2022 topline data presentation of the MISSION Phase 2 clinical trial. Today's presentation will be followed by a question-and-answer session. I would now like to hand the call over to John Fowler, Chief Executive Officer and Co-Founder of Kezar Life Sciences. Go ahead, John.
Thank you for the introduction, Alex, and good afternoon, everyone. Thank you all for joining us today as we present the topline data for MISSION, our clinical trial investigating zetomipzomib for the treatment of lupus nephritis.
Here are our disclaimers.
Now, the second quarter has been very busy for us, having completed not one but two clinical trials. As you read from our press release, we have exciting, positive and meaningful results to share with you today, so I'm not going to delay jumping into the MISSION trial data. But here is the outline for the next hour.
Kezar just celebrated its seventh birthday, and it's been a true pleasure to work with my dear friend
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)